N/A
Completed N=186
A Family-Based Diabetes Intervention for Hispanic Adults in an Emerging Community
Source: ClinicalTrials.gov NCT02114814 ↗Enrolled (actual)
186
Serious AEs
0.0%
Results posted
Feb 2021
Primary outcomePrimary: Hemoglobin A1C — 8.5; 9.4 mean percentage of HbA1c
Summary
The aim of this study was to compare the efficacy of an intervention and an attention control group in producing changes in diabetes self-management, glycemic control (HbA1c) and health related quality of life in Hispanics with type 2 diabetes.
Hypothesis: The experimental group who receive an 8 week intervention program would show significantly greater improvements than an attention control group at 1 and 6 months after the intervention in: behavioral influences of diabetes knowledge, diabetes self-efficacy, and family support, outcomes of self-reported management of diabetes (physical activity, diet, medications, and glucose monitoring), HbA1c levels, and psychological outcomes of health-related quality of life.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Hemoglobin A1C |
8.4; 8.2 | — |
| SECONDARY Health-related Quality of Life (SF-12) |
53.3; 50.3; 48.9; 55.7 | — |
Eligibility Criteria
Inclusion Criteria for participants:
- Community-dwelling
- Self-identification as Hispanic
- Age 18 years or older
- Self-identification as having a medical diagnosis of type 2 diabetes
- An adult family member willing to participate in the study.
- Must be able to speak either English or Spanish
Inclusion criteria for family members/relatives are:
- Family member is over 18
- Reside in the same household as the participant with diabetes
- Must be able to speak either English or Spanish
Exclusion Criteria
We will exclude Hispanic adults and family members who are:
- diagnosed with type 1 diabetes
- report prior (within the past year) or current participation in other diabetes self-management intervention programs
- cognitively impaired (not oriented to time, place, or person, or with known dementia)
- Pregnant at the time of T1 (baseline) data collection
Data sourced from ClinicalTrials.gov (NCT02114814). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.